1. Home
  2. UG vs BTAI Comparison

UG vs BTAI Comparison

Compare UG & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United-Guardian Inc.

UG

United-Guardian Inc.

N/A

Current Price

$7.21

Market Cap

29.9M

ML Signal

N/A

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

HOLD

Current Price

$1.07

Market Cap

35.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UG
BTAI
Founded
1942
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.9M
35.6M
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
UG
BTAI
Price
$7.21
$1.07
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$23.00
AVG Volume (30 Days)
3.2K
1.0M
Earning Date
05-07-2026
05-11-2026
Dividend Yield
7.35%
N/A
EPS Growth
N/A
75.63
EPS
0.20
N/A
Revenue
$10,545,468.00
N/A
Revenue This Year
N/A
$197.82
Revenue Next Year
N/A
$910.15
P/E Ratio
$34.25
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.58
$1.01
52 Week High
$9.88
$8.08

Technical Indicators

Market Signals
Indicator
UG
BTAI
Relative Strength Index (RSI) 66.99 36.89
Support Level $6.21 N/A
Resistance Level $7.70 $1.26
Average True Range (ATR) 0.15 0.08
MACD 0.04 0.02
Stochastic Oscillator 84.40 24.49

Price Performance

Historical Comparison
UG
BTAI

About UG United-Guardian Inc.

United-Guardian Inc manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. Its product portfolio includes Klensoft, Deselex, Renacidin, Lubrajel Fluid. The company's pharmaceutical products are sold to and distributed by full-line drug wholesalers throughout the United States. Its medical and specialty industrial products are sold directly by the company to the end-users of those products or, in some cases, to contract manufacturers used by some of those end users. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. It derives key revenue from the sales made in the U.S.

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: